Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Jacquelot

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
European Journal of Immunology|July 24, 2025
LAG3 Marks Activated but Hyporesponsive NK CellsValeria Vasilyeva, Olivia Makinson, Cynthia Chan, et al.
Cancer Immunology Research|March 14, 2025
CD103+CD56+ ILCs Are Associated with an Altered CD8+ T-cell Profile within the Tumor MicroenvironmentDouglas C Chung, Noor Shakfa, Jehan Vakharia, et al.
Cell Research|January 14, 2015
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Dalil Hannani, Marie Vétizou, David Enot, et al.
Cell Research|September 5, 2019
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockadeNicolas Jacquelot, Takahiro Yamazaki, Maria P Roberti, et al.
Immunity|October 9, 2016
Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory EffectsRomain Daillère, Marie Vétizou, Nadine Waldschmitt, et al.
Science (New York, N.Y.)|November 7, 2015
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaMarie Vétizou, Jonathan M Pitt, Romain Daillère, et al.
Nature Immunology|June 8, 2021
Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanomaNicolas Jacquelot, Cyril Seillet, Minyu Wang, et al.
EMBO Molecular Medicine|December 29, 2020
Immunodynamics of explanted human tumors for immuno-oncologyAgathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsBertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
European Journal of Immunology|July 24, 2025
LAG3 Marks Activated but Hyporesponsive NK CellsValeria Vasilyeva, Olivia Makinson, Cynthia Chan, et al.
Cancer Immunology Research|March 14, 2025
CD103+CD56+ ILCs Are Associated with an Altered CD8+ T-cell Profile within the Tumor MicroenvironmentDouglas C Chung, Noor Shakfa, Jehan Vakharia, et al.
Cell Research|January 14, 2015
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Dalil Hannani, Marie Vétizou, David Enot, et al.
Cell Research|September 5, 2019
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockadeNicolas Jacquelot, Takahiro Yamazaki, Maria P Roberti, et al.
Immunity|October 9, 2016
Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory EffectsRomain Daillère, Marie Vétizou, Nadine Waldschmitt, et al.
Science (New York, N.Y.)|November 7, 2015
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaMarie Vétizou, Jonathan M Pitt, Romain Daillère, et al.
Nature Immunology|June 8, 2021
Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanomaNicolas Jacquelot, Cyril Seillet, Minyu Wang, et al.
EMBO Molecular Medicine|December 29, 2020
Immunodynamics of explanted human tumors for immuno-oncologyAgathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsBertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Pageof 6